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Langerhans cells (LC) are the principal dendritic cell (DC) population in the epidermis of
the skin. Owing to their prominent position at the environmental barrier, LC have long
been considered to be prototypic sentinel DC. More recently, the precise role of LC in the
initiation and control of cutaneous immune responses has become debatable. To elucidate
their contribution to immune regulation in the skin, our laboratories have generated
genetically modified mice in which LC can be followed in situ by expression of enhanced
green fluorescent protein and can be either inducibly or constitutively depleted in vivo.
This review highlights the similarities and differences between these mouse models,
discusses the discovery and functional significance of Langerin1 dermal DC, and exam-
ines some recent data that help to shed light on LC function.
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The Langerhans cell paradigm
Langerhans cells (LC) were discovered by Paul Langerhans in
1868 [1], but it took more than 100 years before they were first
associated with the immune system and recognized as antigen-
presenting cells [2]. In particular, Ralph Steinman’s group [3]
dissected the functional characteristics of LC starting from the
seminal finding that murine epidermal LC mature into potent
immunostimulatory dendritic cells (DC) in vitro. The work that
followed shaped the concept of DC as professional inducers
of T-cell immune responses largely by studying LC, though the
term ‘LC paradigm’ was coined much later by Wilson and
Villadangos [4].
This concept assigned three key functions to LC/DC (reviewed
in [5]). First, immature LC that reside in the periphery in the
steady state are highly specialized in antigen uptake. LC form
a dense network in the epidermis where they constantly scan
the environment by extending and retracting their dendrites
and are ideally positioned to detect any pathogen breaching
the skin barrier [6]. Second, LC transport antigen to skin-
draining lymph nodes (LN), which is essential to ensure inter-
action with rare antigen-specific naive T cells. Stimulation
by a number of pathogen products in addition to pro-inflamma-
tory cytokines induces LC activation [7–9]. Activated LC down-
regulate expression of E-cadherin, which is thought to
maintain their position in the epidermis, and begin to express CC
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chemokine receptor 7, which guides the cells to the T-cell areas in
the LN.
Third, during migration the LC undergo a process
of maturation in which they process antigen acquired in the
skin and present it in the context of MHC class I/II. In addition,
they dramatically upregulate their surface expression of
co-stimulatory molecules and start to produce cytokines required
for proper Th1 or Th2 instruction. Thus, by the time LC arrive
in the LN, they have acquired the surface phenotype of a
‘functionally’ mature DC capable of activating naive T cells and
thereby initiating an adaptive immune response specifically
tailored to fight off the invading cutaneous pathogen [5].
The LC paradigm has been expanded to include LC that
migrate to skin-draining LN in the steady state in the absence of
activating stimuli where they present self-peptides to T cells
[10–14]. This steady-state presentation of self-antigens has been
proposed to eliminate self-reactive T cells and provide a
mechanism of peripheral tolerance [15, 16]. Hemmi et al. [17]
showed that an epidermally restricted self-antigen is transported
to draining LN by TGF-b-dependent cells, presumably LC.
In addition, targeted delivery of antigen in the immunological
steady state, via the endocytic receptor CD205 expressed
on immature DC (including LC), failed to induce immunity
and instead established CD4 and CD8 T-cell tolerance
possibly through the induction of regulatory T cells [18–20].
Recent evidence suggests that disruption of E-cadherin interac-
tions used by LC to remain tethered in the epidermis
and associated b-catenin signaling may participate in this
process [21].
The first suggestion that the LC paradigm does not explain all
aspects of skin-adaptive immunity arose from work with herpes
simplex virus (HSV) infection models. During murine HSV2
infection of the vaginal epithelium, CD8a1 CD45RA CD11b1
submucosal DC, thought to be the equivalent of dermal DC
(dDC), and not LC were responsible for the induction of a
protective CD41 Th1 response [22]. In addition, in a cutaneous
HSV1 infection, LC were incapable of priming CD81 T cells but
rather appeared to transfer their antigenic cargo to the priming
LN-resident CD8a1 DC population. Importantly, the authors did
not exclude a role for antigen uptake and transport to the LN by
LC, only direct MHC class I-restricted antigen presentation and
CTL priming [23]. An important caveat, however, is that HSV
infection is lytic, known to induce DC apoptosis [24] and liber-
ates many apoptotic cell particles that may travel as free material
into the LN. Antigens from non-lytic viruses such as lentiviruses
are directly presented by skin-derived DC and not CD8a1
DC [25].
Generation of three LC-deficient mouse
models
A major obstacle to examining the functional requirement for
LC (and other DC) in skin immunity was the absence of mice with
a selective LC deficiency. Unlike T or B cells, where ablation of a
single gene can lead to the absence of an entire cell
type, an equivalent gene for LC had not been identified.
Thus the discovery of Langerin, a C-type lectin expressed by LC
that is responsible for the generation of Birbeck granules, which
are the ultrastructural hallmark of LC, was met with great
excitement [26]. Although Langerin is dispensable for LC
development [27], the identification of a gene that is selectively
expressed by LC proved quite valuable and was exploited
by our three groups (B.C.: Dutch group; A.K.: French group;
D.K.: American group) to direct expression of either the
diphtheria toxin (DT) receptor (DTR) or subunit A of DT
itself (DTA) to LC in an effort to generate mice with a selective
deficit of LC.
DT is a heterodimeric protein. Binding of the B subunit to
heparin-binding EGF-like growth factor (HB-EGF) precursor on
the surface of mammalian cells facilitates entry of DTA into the
cell. Once inside the cell, DTA inhibits protein biosynthesis and
induces rapid cell death. The rodent homologue of HB-EGF
precursor does not bind to the B subunit of DT, which prevents
internalization of DTA and renders mice resistant to DT [28].
Transgenic expression of the high-affinity human HB-EGF
precursor, henceforth referred to as DTR, in a particular murine
cell type such as LC makes these cells sensitive to DT and enables
their inducible depletion in vivo after exogenous introduction
of DT.
To achieve inducible ablation of LC, two of our groups
generated knock-in mice of the human DTR into the langerin
locus (Langerin–DTR–EGFP). The Dutch group targeted a
DTR–EGFP cassette into the second exon of the langerin gene
[29]. The French group generated two separate lines in which
either an IRES–EGFP or an IRES–DTR–EGFP cassette was
knocked-in to the sixth exon, in the 30-untranslated region of
langerin [30]. In F1 mice, LC were sensitive to DT and expressed
high levels of EGFP. In both the Dutch and French mice,
epidermal LC are efficiently depleted within 24–48h following a
single systemic (i.p.) injection of DT. Repopulation of the
depleted epidermis is slow with patches of LC starting to reappear
only at 2–4 wk post-DT injection. Although langerin was thought
to be expressed only by epidermal LC, a subset of CD8a1 DC
found throughout the secondary lymphoid tissues (LN, spleen
and thymus) also express Langerin and are ablated after DT
administration [30].
Our third (American) group used an alternative approach and
generated bacterial artificial chromosome (BAC)-transgenic mice
by inserting DTA (not DTR) into the 30-untranslated region of the
langerin gene contained within a 70-kb fragment of human
genomic BAC DNA [31]. Since DTA is expressed coordinately
with Langerin, the resulting Langerin-DTA (American) mice
have a constitutive and durable absence of LC. Interestingly,
unlike in the Langerin–DTR–EGFP mice, only epidermal
LC and no other Langerin1 DC are ablated in the DTA mice.
This presumably reflects altered regulation of expression of the
human langerin promoter compared with the endogenous
mouse promoter driving DTR expression in the Dutch and
French mice.
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Contact hypersensitivity in the absence of LC
Contact hypersensitivity (CHS) to epicutaneously applied hapten
is a classic assay for examining cutaneous adaptive immunity. In
this assay, mice are sensitized by the application of hapten on
shaved abdominal skin and are then challenged 5 days later by
painting the same hapten onto the ear (Fig. 1). The degree of
inflammation is quantified by the amount of ear swelling that
develops. The challenge measures the extent of anti-hapten
effector T-cell responses and not memory responses [32].
Prevailing views of LC function in CHS would predict that LC-
deficient mice would exhibit an absent or greatly diminished CHS
response [33, 34].
To determine the functional requirement for LC, each of our
three groups examined CHS responses in the absence of LC
(Table 1). When the French Langerin–DTR–EGFP mice were
sensitized and challenged using a standard dose of dinitro-
fluorobenzene (DNFB), there was no difference in ear swelling
between mice treated with DT 3 days prior to and 1 day after
sensitization and controls [30]. This suggested that LC are
dispensable for the induction of CHS responses. In contrast,
Dutch Langerin–DTR–EGFP mice treated with DT 3 days prior to
sensitization developed diminished but not absent CHS in
response to a standard dose of another hapten, trinitro-
chlorobenzene, suggesting that LC are required for optimal
initiation of CHS responses [29]. Finally, the American Langerin–
DTA mice, constitutively lacking LC, developed enhanced CHS
responses compared with littermate controls to both DNFB and a
third hapten, oxazalone [31]. This was interpreted as showing
that LC have a regulatory role and limit CHS responses. The
altered CHS responses observed in the Dutch and American mice
were antigen-specific and required the absence of LC during the
sensitization and not challenge phases [30, 31, 35]. Thus, rather
than establishing a precise role for LC, there were divergent
results for CHS (no change, decreased and increased) in three
independent models of LC deficiency.
Since the French and Dutch mice were generated using an
almost identical strategy, it is particularly surprising that CHS
responses differ between the two. It is likely that rather than
intrinsic differences between the two mouse lines, differences in
CHS experimental technique account for the different results. The
choice of hapten does not seem to be critical since the Dutch mice
also have reduced CHS to oxazalone [35]. Rather, it appears that
the timing of DT administration can affect the outcome since
French mice treated with DT only on day 1 develop diminished
CHS responses similar to the Dutch mice [36, 37]. Thus, even
though the mice have not been compared side-by-side in the same
experiment and minor differences may still exist, it appears that
the two Langerin–DTR lines behave similarly when examined
using a comparable protocol.
Unlike the French and Dutch mice, the American mice were
developed using a significantly different approach that could
explain the dissimilar CHS results. Owing to the constitutive
ablation of LC throughout ontogeny, enhanced CHS may result
from the chronic absence of LC, which may potentially affect the
development of peripheral tolerance as predicted by the LC
paradigm. Another difference is that only epidermal LC and notFigure 1. Schematic of the sensitization process.
Table 1. An overview of discordant CHS results published to datea)
DT (day)b) Mouse line LCc) Langerin1 dDCc) Hapten CHS response
n.a. Langerin–DTA [31]  111 DNFB Enhanced [31]
oxazalone
FITC
4 and 1 Langerin–DTR–EGFP (F) [30]   DNFB Reduced [36, 37]
3 and 1 Langerin–DTR–EGFP (F) [30]  7 DNFB Normal [30, 37]
3 Langerin–DTR–EGFP (NL) [29]  7 Trinitrochlorobenzene Reduced [29, 35]
oxazalone, low dose
14, 10 or 7 Langerin–DTR–EGFP (F) [30]  1 DNFB Normal [36]
FITC Normal (C. Hauser,
unpublished data)
28 Langerin–DTR–EGFP (NL) [29] 7 11 Oxazalone, low dose Reduced [35]
a) The flanks of mice were sensitized to hapten at day 0 and challenged with hapten at day 5. CHS response (ear swelling)
was monitored 24–48 h following challenge.
b) Dutch (NL) and French (F) inducible ablation models were treated with DT at varying time points (days) prior to and
after sensitization. Langerin–DTA mice exhibit constitutive LC ablation and therefore do not require DT-induced
ablation; n.a., not administered.
c) Number of cells at the time of sensitization.
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other Langerin1 cells are ablated in the American mice, a finding
that is further discussed below.
Langerin is expressed by DC other than LC
Over the last 3 years it has become increasingly clear that
Langerin is not a specific marker for LC and that it is expressed by
other non-epidermal DC subsets. Utilizing Langerin–EGFP knock-
in mice it became apparent that the majority of blood-derived
CD81 DC in the thymus, spleen, cutaneous LN (CLN) and
mesenteric LN also express lower levels of Langerin, depending
on the genetic background (Table 2) [30, 38, 39]. Langerin1
CD8 (CD1031CD11b) DC have also been described in the lung
specifically localized at the basal lamina of the bronchial epithelia
and arterioles of the lung [40].
Initial studies with the Dutch and French Langerin–
DTR–EGFP models demonstrated that DT treatment efficiently
ablated LC in the epidermis, as well as LC and blood-derived
CD81 Langerinlo DC in the CLN. Contrary to expectation
it was observed that the reconstitution of Langerin1 DC popula-
tions in CLN preceded the reconstitution of LC in the epidermis
by a couple of weeks and reappeared with similar kinetics
to the blood-derived CD81 Langerinlo DC [30, 35]. This suggested
that either LC were capable of homing to CLN without trafficking
through the epidermis or that another Langerin1 DC subset
existed. Although Langerin1 MHC class II1 DC in the dermis
had already been observed, they were always assumed to be
transitory LC migrating from the epidermis to the draining
LN [30, 35]. Utilizing the three available mouse models
(French, American and Dutch mice) and a variety of techniques,
three groups were able to demonstrate the presence of
a radio-sensitive Langerin-expressing dDC subset, which
is independent of epidermal LC. This observation has
important implications for the interpretation of previous
functional studies on LC using the Langerin–DTR–EGFP ablation
models.
Langerin1 dermal DC
Recently, three groups described the existence of a novel
Langerin1 DC subset in the dermis that is independent of
‘classical’ LC of the epidermis [36, 41, 42]. Bone marrow (BM)
reconstitution studies with either congenic strains (CD45.1 BM
into CD45.2 recipients or CD45.1 BM into Langerin–DTR–EGFP
recipients) demonstrated that a Langerin1 skin-derived DC subset
is capable of reconstituting both the dermis and CLN of host mice
while the epidermal LC remain of recipient origin [36, 41, 42].
This suggests that Langerin1 dDC and LC originate from two
distinct developmental pathways. Furthermore, DT ablation
studies in Langerin–DTR–EGFP versus CD45.1 parabiotics demon-
strated that 18 days following DT administration, the epidermis
of parabiotized Langerin–DTR–EGFP mice remained LC-free but
both the dermis and CLN of Langerin–DTR–EGFP mice contained
Langerin1 dDC [41]. Bursch et al. [36] took advantage of the
Langerin–DTA model, which displays constitutive ablation of LC
in the epidermis and CLN from birth but exhibits normal numbers
of other Langerin1 DC subsets. By crossing the Langerin–DTA
with the Langerin–EGFP model they unequivocally demonstrate
that Langerin1 CD8 DC can be found in both the skin dermis
and CLN in a LC-free background. Together these studies
demonstrate the true existence of a Langerin1 dDC subset.
During steady state, Langerin1 dDC originate from a radio-
sensitive blood-derived precursor that is recruited to the dermis
and can migrate to CLN independently of LC. Parallel analysis of
skin and CLN of DT-treated BM chimeras (Langerin–DTR–EGFP
BM into CD45.1 recipients) found that Langerin1 dDC reappear
in the skin 4 days following DT treatment and with a slight lag in
the CLN, as would be expected, demonstrating that this novel DC
subset is capable of replenishing their tissue ‘niche’ significantly
faster than LC of the epidermis [36,42]. Furthermore, Langerin1
dDC and Langerin dDC exhibit significantly accelerated BrdU
incorporation (50% have divided during the 7 days of BrdU
administration) compared with significantly lower incorporation
of BrdU in LC [42].
Table 2. Comparison of skin DC subset phenotypes and their ablation in Langerin–DTR (French and Dutch) mice and
Langerin–DTA (American) micea)
Epidermal LC Langerin1 dDC Langerin dDC CD81 Langerin1 DC
Tissue of residence skin, epidermis skin, dermis skin, dermis LN, spleen, thymus
Langerin expression 111 111  1
CD8    1
CD103  1  n.d.
CD11b 1  1 n.d.
Ep-Cam 1   n.d.
Origin in chimeras host donor donor donor
Depletion in Langerin–DTR mice yes yes no yes
Duration of depletion in Langerin–DTR mice weeks days n.a. days
Depletion in Langerin–DTA mice yes no no no
Duration of depletion in Langerin–DTA mice constitutive n.a. n.a. n.a.
a) See text for references; n.d., not determined; n.a., not affected.
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Although Langerin1 dDC are phenotypically very similar to LC
in expression levels of maturation and co-stimulatory molecules,
they can be distinguished from LC using CD103 (integrin-aIEL
chain), CD11b (integrin-aM) and the adhesion molecule Ep-CAM
(gp40) (Table 2) [36]. Langerin1 dDC are CD11blo, CD1031,
Ep-CAMlo, while LC are CD11bhi, CD103–, Ep-CAMhi. Both
cell types maintain their phenotype in the skin and CLN.
Interestingly, Langerin1 dDC are phenotypically very similar to
Langerin1 DC populations found in the lung, and it is yet unclear
whether these two populations are mutually exclusive or together
constitute a Langerin1 interstitial DC subset [36, 40]. Recent
experiments demonstrate that clearance of influenza virus from
the lung depends on this migratory Langerin1 DC subset [43].
Function of Langerin1 dermal DC versus LC
in CHS
Langerin1 dDC can capture, process and present antigen to
effector cells in the CLN. OVA peptide-pulsed Langerin1 dDC are
capable of presenting antigen peptide and stimulating T-cell
proliferation [36]. Ginhoux et al. [41] took advantage of the YAe
monoclonal antibody, which recognizes an MHC class II I-E-
derived peptide presented in the context of MHC class II I-Ab.
They generated chimeras using F1 (C57BL/6 I-Ab–/–  BALB/c
I-Ed1) mice reconstituted with C57BL/6 I-Ab1/1 BM; thus only
donor cells and not LC would be capable of presenting I-Ed-
derived peptide. LC in the skin did not stain for YAe, whereas
both Langerin1 dDC and Langerin– dDC, and only donor-derived
Langerin1 DC in the CLN stained positive for YAe.
As already mentioned, Langerin1 dDC- and CD81 DC-expres-
sing Langerin are deleted after DT administration into Langer-
in–DTR–EGFP mice. However, unlike epidermal LC, which do not
repopulate the epidermis until at least several weeks after DT
administration, these other Langerin1 DC begin to return within a
few days and reach approximately 50% of their steady-state levels
by 2wk. This provided a time window in which to assess their
relative roles in CHS. Using a standard dose of hapten, CHS
responses are greatly diminished in Langerin–DTR–EGFP mice
when DT is administered on day 1 before sensitization with
DNFB. However, when mice are sensitized 7 or 13 days after DT
treatment, at a time when only the epidermal LC remain absent,
CHS responses have returned to normal [36]. CHS experiments
using a standard dose of FITC as a hapten give a similar result
(Conrad Hauser, unpublished observations). From these studies, it
appears that Langerin1 dDC but not LC are critical for the devel-
opment of efficient CHS responses (Table 2).
These observations are apparently inconsistent with a study
showing that the Dutch Langerin–DTR–EGFP mice sensitized with
a low dose of oxazalone 4wk after DT, when most LC are still
absent but all other Langerin1 DC populations have largely
recovered from the toxin treatment, exhibit reduced CHS respon-
ses [35]. The most likely explanation to reconcile these deviating
observations with the two inducible Langerin–DTR models is that
the dose of hapten is important. At standard doses of hapten
sensitization, antigen is delivered to both the LC in the epidermis
as well as DC in the dermis. When both DC populations acquire the
antigen, presentation by LC is redundant for the development of a
response. However, when antigen is limiting and preferentially
acquired by LC, then their absence leads to diminished CHS.
The identification of a novel population of dDC that are
eliminated in Langerin–DTR–EGFP mice but not in Langerin–DTA
mice most likely explains why Langerin–DTA mice do not develop
decreased CHS responses and partially reconciles the discordant
findings between the LC-deficient models. However, Langerin–
DTR–EGFP mice treated with DT 7 or 13 days (or 4wk) before
sensitization when they still lack all or most epidermal LC do not
display the enhanced CHS observed in Langerin–DTA mice. If LC
are regulatory, then their selective absence should lead to
enhanced CHS similar to that observed in the Langerin–DTA
mice. One interpretation is that the still reduced levels of dDC
and/or CD81 Langerin1 DC prevented what otherwise would
have been an enhanced response in the absence of LC.
Alternatively, the steady-state absence of epidermal LC in
Langerin–DTA mice could inhibit the development of regulatory
mechanisms such as the development of regulatory T cells and
result in enhanced CHS.
Recently, it was shown in a minor-mismatch skin transplan-
tation model using Langerin–DTA mice that the presence of LC in
the donor skin is required for long-term graft acceptance [44].
This supports the notion that LC are regulatory cells and is
consistent with the observed enhancement of CHS responses in
these mice. It is interesting to note that in this model, the regu-
latory capacity of LC can be transferred with the skin and is not
dependent on cells in lymphoid tissue where regulatory T cells
would be expected to reside.
Conclusions
The generation of three independently derived mouse strains that
target LC has enabled the first functional examination of a discrete
DC subset in vivo and led to a wealth of new insights. The
availability of multiple LC-deficient models has enabled us to
examine the role of LC from slightly different angles (Fig. 2,
Table 1). From work with the two Langerin–DTR–EGFP mouse
strains in the setting of an acute depletion of LC, it appears that
when antigen is targeted preferentially to LC such as with low-dose
hapten, then LC appear to be stimulatory and their absence leads to
diminished CHS responses. However, when antigen is simulta-
neously targeted to LC and dDC such as in the setting of normal
hapten doses, then LC appear largely redundant and CHS responses
are mediated by dDC. This is consistent with a model in which all
skin DC have similar function and the number that migrate to the
CLN carrying antigen determines the ultimate outcome.
In contrast, Langerin–DTA mice have a constitutive absence of
only epidermal LC and not other Langerin1 DC. CHS responses and
skin graft rejection are exaggerated in these mice. In this setting,
dDC are presumably sufficient to mediate CHS/graft rejection but
the absence of LC leads to a loss of regulation and an exaggerated
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response. These data are more consistent with a model in which LC
have a unique function distinct from other skin DC. A central
unresolved issue is whether it is the constitutive absence of LC and/
or the selective absence of LC in the Langerin–DTA mice that leads
to enhanced immune responses.
In an effort to sort out these functions, we are actively
examining how LC might mediate their effects. We are in the
process of systematically comparing CHS using high- and low-
dose hapten in both Langerin–DTR and Langerin–DTA mice
within the same laboratory to ensure consistent experimental
technique. Generation of Langerin–DTA Langerin–DTR–EGFP
F1 animals will allow us to compare CHS responses after acute LC
depletion with steady-state LC depletion within the same
experiment. In addition, we have already generated BAC-trans-
genic mice with LC-specific expression of Cre recombinase [45].
We are breeding them to a number of mice with ‘floxed’ genes of
interest and plan to use them to elucidate which genes participate
in LC-mediated immune regulation. To complement this model,
we are also in the process of generating mice in which Cre is
‘knocked-in’ to the murine langerin locus, which we expect to
result in Cre expression in all Langerin1 DC subsets. We antici-
pate that these new efforts will provide further insight into the
functional role of LC in cutaneous immunity.
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